source
- Sarepta appoints former AbbVie executive Michael Severino as new CEO to drive turnaroundSarepta Therapeutics announced that Michael Severino will become its chief executive officer on July 28, succeeding Doug Ingram who plans to retire. Severino brings more than two decades of experi…
- Argenx to acquire Forte Biosciences for $2.2 billion, adding anti-CD122 antibody FB102Argenx announced it will buy Texas‑based Forte Biosciences in a transaction valued at roughly $2.2 billion. The offer of $77 per share represents an 86 % premium to Forte’s recent average price. T…